Skip to main content

Table 2 Significant positively (and negatively) selected genes and pathways that have experimental support in different comparisons

From: MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens

Dataset Comparisons Direction Genes or pathways FDR Rank Experimental support
Leukemia HL-60, KBM7, treatment versus control Positive MAP4K3 0.14 9 [22]
EPM2A 0.14 10 [23]
Negative KEGG: ribosome 4.71E-4 1/181 [3]
HL-60 versus KBM7 Negative IGF1R 1.98E-3 1 [30]
KBM7 versus HL-60 Negative BCR 1.60E-3 7 [31]
ABL1 1.98E-3 18
KEGG: chronic myeloid leukemia 9.00E-4 6/181
Melanoma PLX treatment versus control (14 days) Positive CDH13 0.017 9 [20],[21]
PPT1 0.085 14 [19]
NF1, NF2, MED12, CUL3, TADA1, TADA2B <0.031 11 (max) [4]
Negative RREB1 0.050 1 [25],[26]
PLX treatment versus control (7 days) Positive NF1, NF2, MED12, CUL3, TADA1, TADA2B <0.030 26 (max) [4]
Negative EGFR 0.025 6 [28],[29]
REACTOME: SHC1 events in EGFR signaling 0.069 1/676
REACTOME: signaling by constitutive active EGFR 0.069 2/676
DMSO treatment 14 days versus 7 days Negative KEGG: oxidative phosphorylation 3.30E-3 2/181 [18]
ESC ESC versus plasmid Positive TRP53 0.010 1 [24]
Negative KEGG: ribosome 2.83E-4 1/181 [6]
NANOG, POU5F1, RAD51, BRCA1 <0.016 217 (max)
  1. For other top ranked genes, see Tables S3 to S10 in Additional file 2 and Tables S10 to S18 in Additional file 3.